Is MDCLF or RYLD a better dividend investment in 2026?

MDCLF currently yields 5.82% with a 5% 5-year dividend growth rate. RYLD yields 12.39% with 5% growth. The better choice depends on your goal: RYLD offers higher current income.

What is the dividend yield difference between MDCLF and RYLD?

MDCLF has a forward dividend yield of 5.82% ($2.00/share annually). RYLD yields 12.39% ($1.81/share annually). The yield gap is 6.57 percentage points.

Home › Compare › MDCLF vs RYLD

MDCLF vs RYLD: Dividend Comparison 2026

MDCLF yields 5.82% · RYLD yields 12.39%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 RYLD wins by $15.9K in total portfolio value

INVESTMENT

TIME HORIZON10 years

MDCLF

● Live price

5.82%

Share price

$34.39

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$29.3K

Annual income

$842.73

Full MDCLF calculator →

RYLD

● Live price

12.39%

Share price

$14.64

Annual div

$1.81

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$45.3K

Annual income

$2,682.98

Full RYLD calculator →

Portfolio growth — MDCLF vs RYLD

📍 RYLD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	MDCLF	RYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, MDCLF + RYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

MDCLF pays

RYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MDCLF

Annual income on $10K today (after 15% tax)

$494.33/yr

After 10yr DRIP, annual income (after tax)

$716.32/yr

RYLD

Annual income on $10K today (after 15% tax)

$1,053.44/yr

After 10yr DRIP, annual income (after tax)

$2,280.53/yr

At 15% tax rate, RYLD beats the other by $1,564.21/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MDCLF + RYLD for your $10,000?

MDCLF: 50%RYLD: 50%

100% RYLD50/50100% MDCLF

Portfolio after 10yr

$37.3K

Annual income

$1,762.85/yr

Blended yield

4.73%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on MDCLF right now

MDCLF

Analyst Ratings

Buy

Consensus: Buy

Altman Z

5.5

Piotroski

5/9

RYLD

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MDCLF buys

RYLD buys

No recent congressional trades found for MDCLF or RYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricMDCLFRYLD

Forward yield	5.82%	12.39% ✓
Annual dividend / share	$2.00 ✓	$1.81
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$29.3K	$45.3K ✓
Annual income after 10y	$842.73	$2,682.98 ✓
Total dividends collected	$7.2K	$19.4K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: MDCLF vs RYLD ($10,000, DRIP)

Year	MDCLF Portfolio	MDCLF Income/yr	RYLD Portfolio	RYLD Income/yr	Gap
1← crossover	$11,282	$581.56	$11,939	$1,239.34	$657.00 → RYLD
2	$12,684	$613.17	$14,158	$1,382.89	$1.5K → RYLD
3	$14,217	$644.32	$16,682	$1,532.59	$2.5K → RYLD
4	$15,887	$674.91	$19,537	$1,687.64	$3.6K → RYLD
5	$17,704	$704.85	$22,752	$1,847.20	$5.0K → RYLD
6	$19,677	$734.08	$26,355	$2,010.43	$6.7K → RYLD
7	$21,817	$762.53	$30,376	$2,176.45	$8.6K → RYLD
8	$24,134	$790.14	$34,847	$2,344.43	$10.7K → RYLD
9	$26,641	$816.89	$39,800	$2,513.54	$13.2K → RYLD
10	$29,348	$842.73	$45,269	$2,682.98	$15.9K → RYLD

MDCLF vs RYLD: Complete Analysis 2026

MDCLF — Stock

MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.

Full MDCLF Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →

📬

Get this MDCLF vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MDCLF vs SCHD MDCLF vs JEPI MDCLF vs O MDCLF vs KO MDCLF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.